Management

Joshua N. Silverman is currently the Co-Founder and Managing Member of Parkfield Funding LLC and is a former Principal and Managing Partner of Iroquois Capital Management, LLC. Mr. Silverman served as Co-Chief Investment Officer of Iroquois from 2003 until July 2016. From 2000 to 2003, Mr. Silverman served as Co-Chief Investment Officer of Vertical Ventures, LLC, a merchant bank. Prior to forming Iroquois, Mr. Silverman was a Director of Joele Frank, a boutique consulting firm specializing in mergers and acquisitions. Previously, Mr. Silverman served as Assistant Press Secretary to The President of The United States. Mr. Silverman currently serves on the boards of directors of Ayro Inc., MYMD Pharmaceuticals, Inc., Petros Pharmaceuticals, Inc. and Synaptogenix, Inc. Mr. Silverman received his B.A. from Lehigh University.

Carlos A. Trujillo serves as the Chief Financial Officer of PharmaCyte Biotech. Mr. Trujillo is a Certified Public Accountant licensed by the State of California. He has 35 years of experience in finance, accounting and management. Mr. Trujillo started his career in public accounting and was the manager of an audit department. Mr. Trujillo then established a consulting and accounting practice which he operated for ten years and provided services as the Chief Financial Accountant to numerous organizations in several different industries. His experience has extended to companies in the biotechnology, telecommunications, manufacturing, construction and real estate development sectors.

For the last eleven years, Mr. Trujillo has been the Chief Financial Officer for both privately-held and publicly-traded, multinational companies. He brings extensive experience to PharmaCyte in preparing and filing periodic reports with the Securities and Exchange Commission, in mergers and acquisitions and in the filing of comprehensive financial statements and reports.

Mr. Trujillo received his Bachelor’s Degree in Accounting in 1982 from California State University, Fullerton.

Dr. Iglesias brings a wealth of experience in developing and testing a variety of cancer chemotherapeutic agents to PharmaCyte, including key positions with many prominent biotechnology firms including Eli Lilly, Amgen, Abraxis and Celgene. Dr. Iglesias’s body of work is ideally suited to guide PharmaCyte through its planned Phase 2b clinical trial in LAPC. As the global Vice-President of Clinical Development at Celgene, Dr. Iglesias was the lead physician on the team that obtained FDA approval for Abraxane^® (the nab-paclitaxel/gemcitabine combination), which is a first-line therapy in pancreatic cancer.

Dr. Iglesias has been awarded numerous prestigious fellowships, and he is the co-author of 68 publications in scientific journals.